Introduction
Post-infarction ventricular septal defect (PIVSD) is a rare and devastating complication of acute myocardial infarction (AMI), the prevalence rate is <1%[1]. Even though the patients get prompt medical management, the mortality rate is higher than 90%[1-2]. Until recently, surgery repair as a comprehensive applicant and a generally safe procedure is associated with high morbidity and mortality (20-81%)[1,3]. On the contrary, medical therapy alone has a minimal survival rate of less than 8% at 30 days [4] and less than 3% at one year [1,2,4,5]. Even though the surgical closure presents a modest improvement of mortality compared with medical therapy, surgical intervention own self-limitations like restriction of advanced age, multi perioperative morbidity and surgical expertise are not readily available. It is suggested that the transcatheter closure (TCC) of PIVSD as promising alternative management to cause the less invasive and be recommended by authoritative national guidelines[6-8]. Evolution of the timing of TCC can be broadly categorized into 2 phases: The acute phase occurs within the first two weeks after AMI, which is characterized by coagulation necrosis and release of lytic enzymes from neutrophils resulting in myocardial necrosis; The chronic phase begins after 3–4 weeks and is characterized by fibrosis and scar formation around the edges of the defect. To our knowledge, the actual benefits of TCC proposed for use in the PIVSD remain uncertain. Moreover, the majority of clinical proof is based on limited study sizes. We, therefore, systemically searched and analyzed the available literature to provide physicians and patients an objective estimate of the outcomes of TCC on PIVSD patients in the current era.